BlackRock Greater Europe Investment Trust Plc - Portfolio Update
The information contained in this release was correct as at
https://www.londonstockexchange.com/exchange/news/market-news/market-news-home.html .
All information is at
Performance at month end with net income reinvested
One Three One Three Launch
Month Months Year Years (20 Sep 04)
Net asset value (undiluted) 5.4% -4.1% 3.0% 9.4% 743.8%
Share price 4.6% -6.1% 0.9% 6.8% 692.9%
FTSE World Europe ex UK 4.9% 0.3% 20.4% 41.1% 598.7%
Sources: BlackRock and Datastream
At month end
Net asset value (capital only): 585.54p Net asset value (including income): 593.41p Share price: 550.00p Discount to NAV (including income): 7.3% Net gearing: 7.3% Net yield 1 : 1.3% Total assets (including income): £542.6m Ordinary shares in issue 2 : 91,445,411 Ongoing charges 3 : 0.95%
1
Based on an interim dividend of 1.75p per share and a final dividend of 5.40p per share for the year ended
2
Excluding 26,483,527 shares held in treasury.
3
The Company’s ongoing charges are calculated as a percentage of average daily net assets and using the management fee and all other operating expenses excluding finance costs, direct transaction costs, custody transaction charges, VAT recovered, taxation, write back of prior year expenses and certain non-recurring items for the year ended
Country Analysis Total Assets (%)
Netherlands 20.1
France 18.2
Sector Analysis Total Assets (%) Switzerland 16.8
Industrials 30.8 Germany 10.8
Financials 18.9 Italy 5.8
Technology 17.4 Spain 5.4
Health Care 12.6 Sweden 4.1
Energy 6.2 Denmark 4.0
Consumer Discretionary 5.3 Belgium 3.5
Basic Materials 4.8 Finland 2.9
Utilities 3.3 Ireland 2.9
Net Current Assets 0.7 United States 2.1
----- Norway 1.4
100.0 Austria 1.3
===== Net Current Assets 0.7
-----
100.0
=====
Top 10 holdings Country Fund % ASML Netherlands 8.5 Siemens Germany 6.2 Safran France 4.5 UniCredit Italy 4.1 ASM International Netherlands 3.9 Novartis Switzerland 3.4 Engie SA France 3.4 BE SemiconductorNetherlands 3.1 Kone Finland 3.0 Legrand SA France 3.0
Commenting on the markets,
During the month, the Company’s NAV rose +5.4% and the share price rose +4.6%. For reference, the FTSE World Europe ex
The market tried to move on from the conflict in
Sector allocation effects were positive over the month, primarily driven by overweight positioning to industrials and technology, specifically the semiconductor industry. Being underweight energy and consumer staples also aided allocation effects.
The AI trade was a key driver of performance during the month. BE Semiconductor was a standout contributor, with shares rising by more than 38% over the period. The company reported a robust Q1 update, with orders growing strongly quarter-on-quarter, highlighting accelerating demand from advanced packaging linked to AI applications. ASMi was also a top contributor, delivering sizeable beats across the board in their Q1 results. Revenue growth was 3% ahead of expectations, driven by strength in advanced logic and foundry and positive mix shift contributed to a 10% gross margin beat. Guidance for the rest of the year is strong; sequential growth in H2 implies 30% constant FX revenue growth for the full year.
Industrial companies exposed to data centre infrastructure and electrification also benefited from the positive AI sentiment. Siemens Energy pre-released a 13% group order beat driven by Gas 20% ahead, growing 32% year-on-year, and Grid 25% above consensus, growing 42% year-on-year. Full year guidance was also raised, with expectations for free cash flow almost doubling from €4-5 billion to €8 billion. This reinforced confidence in the strength of demand, particularly in grid technologies, and the improving execution of the business. ABB also reported an impressive 15% beat on orders in Q1, growing 24% organic at a group level, and sales growth guidance was raised for the full year.
MTU and Safran weighed on relative performance as the
Defence holdings –
UCB detracted following the announcement of a €2 billion acquisition of Candid Therapeutics. While there was no change to guidance, the deal brings bispecific antibody capabilities in-house for immunology—aiming to reset the immune system rather than simply control disease. While strategically interesting, the market was taken aback by the upfront cost.
Outlook
From here, we remain observant of buying opportunities presented by a volatile market backdrop. In these environments of rising dispersion, we find there is often opportunity for alpha and we’re using the full scale of a leading team to identify change. The portfolio remains cyclically tilted with key exposures across areas we believe remain well underpinned over the mid to long term such as defence, select industrials, civil aerospace, banks and semiconductor cycle exposure.
ENDS
Latest information is available by typing www.blackrock.com/uk/brge on the internet, "BLRKINDEX" on Reuters, "BLRK" on Bloomberg or "8800" on Topic 3 (ICV terminal). Neither the contents of the Manager’s website nor the contents of any website accessible from hyperlinks on the Manager’s website (or any other website) is incorporated into, or forms part of, this announcement.
Release